BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38148351)

  • 1. Local Therapy Improves Survival for Early Recurrence After Resection of Colorectal Liver Metastases.
    Boyev A; Tzeng CD; Maki H; Arvide EM; Mrema DE; Jain AJ; Haddad A; Lendoire M; Malik N; Odisio BC; Chun YS; Tran Cao HS; Vauthey JN; Newhook TE
    Ann Surg Oncol; 2024 Apr; 31(4):2547-2556. PubMed ID: 38148351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
    Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
    J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.
    Nishioka Y; Paez-Arango N; Boettcher FO; Kawaguchi Y; Newhook TE; Chun YS; Tzeng CD; Tran Cao HS; Lee JE; Vreeland TJ; Vauthey JN
    J Gastrointest Surg; 2022 Apr; 26(4):791-801. PubMed ID: 34725784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
    Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
    J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
    Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
    Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
    Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
    Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
    Newhook TE; Overman MJ; Chun YS; Dasari A; Tzeng CD; Cao HST; Raymond V; Parseghian C; Johnson B; Nishioka Y; Kawaguchi Y; Uppal A; Vreeland TJ; Jaimovich A; Arvide EM; Cristo JV; Wei SH; Raghav KP; Morris VK; Lee JE; Kopetz S; Vauthey JN
    Ann Surg; 2023 May; 277(5):813-820. PubMed ID: 35797554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases.
    Angelsen JH; Viste A; Løes IM; Eide GE; Hoem D; Sorbye H; Horn A
    World J Surg Oncol; 2015 Dec; 13():328. PubMed ID: 26631156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
    Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
    Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival.
    Lillemoe HA; Kawaguchi Y; Passot G; Karagkounis G; Simoneau E; You YN; Mehran RJ; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    J Gastrointest Surg; 2019 Jan; 23(1):84-92. PubMed ID: 30084064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease.
    Lillemoe HA; Passot G; Kawaguchi Y; DeBellis M; Glehen O; Chun YS; Tzeng CD; Aloia TA; Lopez J; Vauthey JN
    Ann Surg; 2022 Aug; 276(2):357-362. PubMed ID: 33351476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases.
    Denbo JW; Yamashita S; Passot G; Egger M; Chun YS; Kopetz SE; Maru D; Brudvik KW; Wei SH; Conrad C; Vauthey JN; Aloia TA
    J Gastrointest Surg; 2017 Jan; 21(1):68-77. PubMed ID: 27334313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status.
    Kawaguchi Y; Kopetz S; Lillemoe HA; Hwang H; Wang X; Tzeng CD; Chun YS; Aloia TA; Vauthey JN
    J Natl Compr Canc Netw; 2020 Nov; 18(11):1500-1508. PubMed ID: 33152698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases.
    Yamashita S; Odisio BC; Huang SY; Kopetz SE; Ahrar K; Chun YS; Conrad C; Aloia TA; Gupta S; Harmoush S; Hicks ME; Vauthey JN
    Eur J Surg Oncol; 2017 Jun; 43(6):1040-1049. PubMed ID: 28187878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases.
    Kawaguchi Y; Newhook TE; Tran Cao HS; Tzeng CD; Chun YS; Aloia TA; Dasari A; Kopetz S; Vauthey JN
    J Gastrointest Surg; 2021 Jan; 25(1):186-194. PubMed ID: 33205306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.